Offstream
news

Peru temporarily suspends Phase III trials of Sinopharm's vaccine after detecting neurological problems in one of its volunteers. Peru's trials for the vaccine were due to conclude this week, after testing around 12,000 people.
2020-12-12

Egypt receives its first shipment of 50,000 of Sinopharm's vaccine, making it the first African country to receive COVID-19 vaccines. The shipment was provided as a gift from the United Arab Emirates, which recently announced that the vaccine had an 86% efficacy based on Phase III testing results.
2020-12-11

The Ministry of Health and Prevention announces the registration of Sinopharm's inactivated virus vaccine BBICP-CorV, after an interim analysis of the Phase III trials showed BBIBP-CorV to have an 86% efficacy against COVID-19 infection.
2020-12-9

Malaysian Science, Technology and Innovation Minister Khairy Jamaluddin signed an agreement with his Chinese counterpart Wang Zhigang to cooperate on the development of a safe and efficacious vaccine, as part of efforts to combat the COVID-19 pandemic.
2020-11-18

Moderna's preliminary results show their vaccine candidate is 94.5% effective at preventing COVID-19 infections. The results also suggest that in cases of COVID-19 infection after vaccination, the vaccine appeared to prevent severe illness.
2020-11-16

Indonesia aims to start administering COVID-19 vaccines early next month, according to the Coordinating Ministry for Maritime and Investment Affairs. Sinopharm and G42 Healthcare will supply five million doses starting next month, CanSino Biologics will supply 100,000 doses that same time, and Sinovac will supply three million doses of CoronaVac by December. All three vaccines are currently in Phase III trials in various countries.
2020-10-12

The European Medicines Agency announces that they will launch a review for vaccines developed by Pfizer and BioNTech.
2020-10-6

The United Arab Emirates approves Sinopharm's vaccine for frontline workers following successful Phase III clinical trials in Abu Dhabi. The WHO-recognized trial began on July 16 and involved 31,000 volunteers.
2020-09-14

Sinopharm began Phase III trials in Peru starting with two dozen people, with the goal to vaccinate 6,000 people between the ages of 18 and 75. So far, Sinopharm has given 30,000 doses to volunteers and another 10,000 participants have received double doses in Bahrain and the United Arab Emirates, with additional trials planned for Morocco and Argentina.
2020-09-10

The United Arab Emirates is expected to impose night curfew to tackle COVID-19 as the country begins a nationwide disinfection campaign.
2020-03-26